Compare Sana Biotechnology Inc (SANA) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vodafone Group Plc American Depositary Shares — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Vodafone Group Plc American Depositary Shares trades at $15.54 (market cap $38.08B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 45.5× Sana Biotechnology Inc's market cap, and Vodafone Group Plc American Depositary Shares pays a 3.26% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vodafone Group Plc American Depositary Shares for 0 Days on average.
| SANA | VOD | |
|---|---|---|
Market Cap | $836.71M | $38.08B |
Volume | 4,507,444 | 3,820,235 |
Sector | Health | Media |
52-Week High | $5.92 | $17.68 |
52-Week Low | $2.68 | $11.17 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $749.96M | $83.23B |
Dividend Yield | — | 3.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vodafone Group Plc American Depositary Shares
Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.
Read more on VOD →
